• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

To development serum Reg4 and OLFM4 as tumor markers and therapeutic targets in castration resistance prostate cancer

Research Project

Project/Area Number 16K11007
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Urology
Research InstitutionHiroshima University

Principal Investigator

Matsubara Akio  広島大学, 医歯薬保健学研究科(医), 教授 (10239064)

Co-Investigator(Kenkyū-buntansha) 亭島 淳  広島大学, 医歯薬保健学研究科(医), 准教授 (20397962)
安井 弥  広島大学, 医歯薬保健学研究科(医), 教授 (40191118)
林 哲太郎  広島大学, 医歯薬保健学研究科(医), 助教 (60612835)
北野 弘之  広島大学, 病院(医), 助教 (60721933)
神明 俊輔  広島大学, 病院(医), 助教 (70749936)
井上 省吾  広島大学, 病院(医), 講師 (90457177)
Research Collaborator Watt Alexander W.  
Black Peter C  
GORIKI akihiro  
Oo Htoo Zarni  
Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords前立腺癌 / 去勢抵抗性前立腺癌
Outline of Final Research Achievements

We showed that serum Reg IV concentration serves as a diagnostic tumor marker with high specificity for prostate cancer. Reg IV expression correlated with tumor progression. Furthermore, Reg IV expression was associated with docetaxel resistance. serum Reg IV concentration is useful as a less invasive and cheaper diagnostic maker in daily urological clinics.

Academic Significance and Societal Importance of the Research Achievements

血清腫瘍マーカーで病勢評価できることは、高額なPET-CTやMRIを繰り返して行うより、より低侵襲で安価であり正確な病勢評価に繋がる可能性がある。血清RegⅣ値は、ELISA安価で測定可能で、安価な低侵襲な診断マーカーであり、病勢評価に有用である。さらに現在のPSAを中心とした診断治療では把握できない抗がん剤耐性の効果予測因子にもなり得る。RegⅣの発現とその血清値は、前立腺癌治療の診断治療の改善に貢献できる可能性を示した。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (2 results)

All 2016 Other

All Int'l Joint Research (1 results) Presentation (1 results)

  • [Int'l Joint Research] Vancouver prostate centre(Canada)

    • Related Report
      2017 Research-status Report
  • [Presentation] REGⅣは去勢抵抗性前立腺癌患者における新規のバイオマーカー候補となる.2016

    • Author(s)
      藤井慎介、亭島淳、永松弘孝、正路晃一、北野弘之、後藤景介、神明俊輔、林哲太郎、大上直秀、安井弥、松原昭郎
    • Organizer
      第75回日本癌学会学術集会
    • Place of Presentation
      横浜市
    • Year and Date
      2016-10-06
    • Related Report
      2016 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi